304 related articles for article (PubMed ID: 35475683)
1. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).
Bergas A; Albasanz-Puig A; Fernández-Cruz A; Machado M; Novo A; van Duin D; Garcia-Vidal C; Hakki M; Ruiz-Camps I; Del Pozo JL; Oltolini C; DeVoe C; Drgona L; Gasch O; Mikulska M; Martín-Dávila P; Peghin M; Vázquez L; Laporte-Amargós J; Durà-Miralles X; Pallarès N; González-Barca E; Álvarez-Uría A; Puerta-Alcalde P; Aguilar-Company J; Carmona-Torre F; Clerici TD; Doernberg SB; Petrikova L; Capilla S; Magnasco L; Fortún J; Castaldo N; Carratalà J; Gudiol C
Microbiol Spectr; 2022 Jun; 10(3):e0229221. PubMed ID: 35475683
[TBL] [Abstract][Full Text] [Related]
2. A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.
Fernández-Cruz A; Alba N; Semiglia-Chong MA; Padilla B; Rodríguez-Macías G; Kwon M; Cercenado E; Chamorro-de-Vega E; Machado M; Pérez-Lago L; García de Viedma D; Díez Martín JL; Muñoz P
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530598
[TBL] [Abstract][Full Text] [Related]
3. Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study.
Hakeam HA; Askar G; Al Sulaiman K; Mansour R; Al Qahtani MM; Abbara D; Aldhayyan N; Dyab N; Afaneh L; Islami M; Al Duhailib Z
J Infect Public Health; 2022 Oct; 15(10):1081-1088. PubMed ID: 36113401
[TBL] [Abstract][Full Text] [Related]
4. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
Albasanz-Puig A; Gudiol C; Parody R; Tebe C; Akova M; Araos R; Bote A; Brunel AS; Calik S; Drgona L; García E; Hemmati P; Herrera F; Ibrahim KY; Isler B; Kanj S; Kern W; Maestro de la Calle G; Manzur A; Marin JI; Márquez-Gómez I; Martín-Dávila P; Mikulska M; Montejo JM; Montero M; Morales HMP; Morales I; Novo A; Oltolini C; Peghin M; Del Pozo JL; Puerta-Alcalde P; Ruiz-Camps I; Sipahi OR; Tilley R; Yáñez L; Gomes MZR; Carratalà J;
BMJ Open; 2019 May; 9(5):e025744. PubMed ID: 31129580
[TBL] [Abstract][Full Text] [Related]
5. High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations.
Chumbita M; Puerta-Alcalde P; Yáñez L; Angeles Cuesta M; Chinea A; Español-Morales I; Fernandez-Abellán P; Gudiol C; González-Sierra P; Rojas R; Sánchez-Pina JM; Vadillo IS; Sánchez M; Varela R; Vázquez L; Guerreiro M; Monzo P; Lopera C; Aiello TF; Peyrony O; Soriano A; Garcia-Vidal C
Microbiol Spectr; 2023 Aug; 11(4):e0067423. PubMed ID: 37367629
[TBL] [Abstract][Full Text] [Related]
6. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
Maraolo AE; Mazzitelli M; Trecarichi EM; Buonomo AR; Torti C; Gentile I
Int J Antimicrob Agents; 2020 Mar; 55(3):105891. PubMed ID: 31923569
[TBL] [Abstract][Full Text] [Related]
8. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection.
Viasus D; Puerta-Alcalde P; Cardozo C; Suárez-Lledó M; Rodríguez-Núñez O; Morata L; Fehér C; Marco F; Chumbita M; Moreno-García E; Fernández-Avilés F; Gutiérrez-Garcia G; Martínez JA; Mensa J; Rovira M; Esteve J; Soriano A; Garcia-Vidal C
Clin Microbiol Infect; 2020 Mar; 26(3):345-350. PubMed ID: 31295551
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.
Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors and Outcomes of Antibiotic-resistant Pseudomonas aeruginosa Bloodstream Infection in Adult Patients With Acute Leukemia.
Zhao Y; Lin Q; Liu L; Ma R; Chen J; Shen Y; Zhu G; Jiang E; Mi Y; Han M; Wang J; Feng S
Clin Infect Dis; 2020 Dec; 71(Suppl 4):S386-S393. PubMed ID: 33367574
[TBL] [Abstract][Full Text] [Related]
12. [Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa].
Pinilla-Rello A; Huarte-Lacunza R; Magallón-Martínez A; Cazorla-Poderoso L; Pereira-Blanco O; Pérez-Moreno M; Larrodé-Leciñena I; Martínez-Álvarez RM; López-Calleja AI
Rev Esp Quimioter; 2021 Oct; 34(5):441-449. PubMed ID: 34154319
[TBL] [Abstract][Full Text] [Related]
13. Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant
Zhen S; Zhao Y; Chen Z; Zhang T; Wang J; Jiang E; Zhang F; Mi Y; Zhu X; Han M; Xiao Z; Wang J; Feng S
Front Cell Infect Microbiol; 2023; 13():1156651. PubMed ID: 37415825
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
Henderson A; Tan E; McCarthy KL; Paterson DL
Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.
Pogue JM; Kaye KS; Veve MP; Patel TS; Gerlach AT; Davis SL; Puzniak LA; File TM; Olson S; Dhar S; Bonomo RA; Perez F
Clin Infect Dis; 2020 Jul; 71(2):304-310. PubMed ID: 31545346
[TBL] [Abstract][Full Text] [Related]
16. Assessing Rates of Co-Resistance and Patient Outcomes in Multidrug-Resistant Pseudomonas aeruginosa.
Appaneal HJ; Caffrey AR; Lopes V; Piehl EC; Puzniak LA; LaPlante KL
Microbiol Spectr; 2022 Oct; 10(5):e0233622. PubMed ID: 36005836
[TBL] [Abstract][Full Text] [Related]
17. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
[TBL] [Abstract][Full Text] [Related]
18. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
Balandin B; Ballesteros D; Ruiz de Luna R; López-Vergara L; Pintado V; Sancho-González M; Soriano-Cuesta C; Pérez-Pedrero MJ; Asensio-Martín MJ; Fernández-Simón I; Rodríguez-Serrano D; Silva A; Chicot M; Iranzo R; Martínez-Sagasti F; Royuela A
Int J Antimicrob Agents; 2021 Mar; 57(3):106270. PubMed ID: 33347991
[TBL] [Abstract][Full Text] [Related]
19.
Royo-Cebrecos C; Laporte-Amargós J; Peña M; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Morales HMP; Brunel AS; García E; Isler B; Kern WV; Palacios-Baena ZR; de la Calle GM; Montero MM; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J; Gudiol C;
Pathogens; 2022 Sep; 11(10):. PubMed ID: 36297188
[TBL] [Abstract][Full Text] [Related]
20. Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.
Jorgensen SCJ; Trinh TD; Zasowski EJ; Lagnf AM; Simon SP; Bhatia S; Melvin SM; Steed ME; Finch NA; Morrisette T; Estrada SJ; Rosenberg JR; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
